NEMEJCOVA, K., R. KOCIAN, C. KOHLER, Jiří JARKOVSKÝ, J. KLAT, A. BERJON, R. PILKA, B. SEHNAL, B. GIL-IBANEZ, E. LUPO, A. PETIZ, O. A. SANCHEZ, P. KASCAK, F. MARTINELLI, A. BUDA, J. PRESL, M. BARAHONA, L. VAN LONHUIJZEN, W. SZATKOWSKI, Luboš MINÁŘ, M. PAKIZ, P. HAVELKA, C. ZORRERO, M. MISIEK, L. C. SNYMAN, D. WYDRA, I. VERGOTE, A. VINNYTSKA, M. REDECHA, M. MICHAL, S. TINGULSTAD, B. KIPP, G. SZEWCZYK, R. TOTH, F. J .D. GARCIA, P. J. C. MARTIN, R. POKA, K. TAMUSSINO, M. LUYCKX, M. FASTREZ, J. C. STARINGER, A. GERMANOVA, A. PLAIKNER, S. BAJSOVA, P. DUNDR, N. MALLMANN-GOTTSCHALK and D. CIBULA. Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2). Online. Cancers. BASEL: MDPI, 2020, vol. 12, No 5, p. 1-13. ISSN 2072-6694. Available from: https://dx.doi.org/10.3390/cancers12051115. [citováno 2024-04-24]
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2)
Authors NEMEJCOVA, K. (203 Czech Republic), R. KOCIAN (203 Czech Republic), C. KOHLER (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), J. KLAT (203 Czech Republic), A. BERJON (724 Spain), R. PILKA (203 Czech Republic), B. SEHNAL (203 Czech Republic), B. GIL-IBANEZ (724 Spain), E. LUPO (32 Argentina), A. PETIZ (620 Portugal), O. A. SANCHEZ (724 Spain), P. KASCAK (703 Slovakia), F. MARTINELLI (380 Italy), A. BUDA (380 Italy), J. PRESL (203 Czech Republic), M. BARAHONA (724 Spain), L. VAN LONHUIJZEN (528 Netherlands), W. SZATKOWSKI (616 Poland), Luboš MINÁŘ (203 Czech Republic, belonging to the institution), M. PAKIZ (703 Slovakia), P. HAVELKA (203 Czech Republic), C. ZORRERO (724 Spain), M. MISIEK (616 Poland), L. C. SNYMAN (710 South Africa), D. WYDRA (616 Poland), I. VERGOTE (56 Belgium), A. VINNYTSKA (804 Ukraine), M. REDECHA (703 Slovakia), M. MICHAL (203 Czech Republic), S. TINGULSTAD (578 Norway), B. KIPP (756 Switzerland), G. SZEWCZYK (616 Poland), R. TOTH (703 Slovakia), F. J .D. GARCIA (724 Spain), P. J. C. MARTIN (724 Spain), R. POKA (348 Hungary), K. TAMUSSINO (40 Austria), M. LUYCKX (56 Belgium), M. FASTREZ (56 Belgium), J. C. STARINGER (32 Argentina), A. GERMANOVA (203 Czech Republic), A. PLAIKNER (276 Germany), S. BAJSOVA (203 Czech Republic), P. DUNDR (203 Czech Republic), N. MALLMANN-GOTTSCHALK (276 Germany) and D. CIBULA (203 Czech Republic, guarantor)
Edition Cancers, BASEL, MDPI, 2020, 2072-6694.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 6.639
RIV identification code RIV/00216224:14110/20:00116028
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/cancers12051115
UT WoS 000539246000056
Keywords in English sentinel lymph node; cervical cancer; metastases
Tags 14110411, 14119612, GPK, GPKonko, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 12/5/2021 13:16.
Abstract
The quality of pathological assessment is crucial for the safety of patients with cervical cancer if pelvic lymph node dissection is to be replaced by sentinel lymph node (SLN) biopsy. Central pathology review of SLN pathological ultrastaging was conducted in the prospective SENTIX/European Network of Gynaecological Oncological Trial (ENGOT)-CX2 study. All specimens from at least two patients per site were submitted for the central review. For cases with major or critical deviations, the sites were requested to submit all samples from all additional patients for second-round assessment. From the group of 300 patients, samples from 83 cases from 37 sites were reviewed in the first round. Minor, major, critical, and no deviations were identified in 28%, 19%, 14%, and 39% of cases, respectively. Samples from 26 patients were submitted for the second-round review, with only two major deviations found. In conclusion, a high rate of major or critical deviations was identified in the first round of the central pathology review (28% of samples). This reflects a substantial heterogeneity in current practice, despite trial protocol requirements. The importance of the central review conducted prospectively at the early phase of the trial is demonstrated by a substantial improvement of SLN ultrastaging quality in the second-round review.
PrintDisplayed: 24/4/2024 06:48